title: Medical Treatment of Acromegaly with Dopamine Agonists or Somatostatin Analogs.
abstract: Treatment of acromegaly aims to correct (or prevent) tumor compression of surrounding tissues by excising the disease-causing lesion and reduce growth hormone (GH) and IGF-1 levels to normal values. When surgery (the usual first-line treatment) fails to correct GH/IGF-1 hypersecretion, medical treatment with dopamine agonists (DAs; particularly cabergoline) or somatostatin analogs (SAs) can be used. The GH receptor antagonist pegvisomant is helpful in patients who are totally or partially resistant to SAs and can be given in association with both SAs and/or DAs. Thanks to this multistep therapeutic strategy, adequate hormonal disease control is achieved in most patients, giving them normal life expectancy. Comorbidities associated with acromegaly generally improve after treatment, but persistent sequelae may nonetheless impair quality of life.
authors: Service d'Endocrinologie et des Maladies de la Reproduction and Centre de Référence des Maladies Endocriniennes Rares de la Croissance, Hôpital Bicêtre, Assistance Publique-Hôpitaux de Paris, and Inserm 1185, Fac Med Paris Sud, Université Paris-Saclay, Le Kremlin-Bicêtre, France.
authors: Philippe
authors: P
authors: Chanson
mesh_terms: D000172:Acromegaly; D000077465:Cabergoline; D018491:Dopamine Agonists / Q000627:therapeutic use*; D004873:Ergolines / Q000378:metabolism*; D013006:Growth Hormone / Q000378:metabolism*; D019382:Human Growth Hormone / Q000031:analogs & derivatives* / Q000378:metabolism / Q000627:therapeutic use; D006801:Humans; D013004:Somatostatin / Q000031:analogs & derivatives / Q000627:therapeutic use*
chemical_list: D018491:Dopamine Agonists; D004873:Ergolines; D019382:Human Growth Hormone; D013004:Somatostatin; D013006:Growth Hormone; D000077465:Cabergoline; C406545:pegvisomant